Meeting
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
Authors
Thomas Cosgriff
Crescent City Research Consortium, Marrero, LA
Thomas Cosgriff , Lin Yang , Anna Alyasova , Dingwei Ye , Andrey Karpenko , Hanzhong Li , Boris Alekseev , Li-ping Xie , Ruben Dario Kowalyszyn , Oleg Karyakin , Yeni Verónica Neron , LaTonya Collins , Thomas Brechenmacher , Chinjune Lin , Liza Morgan , Robert J. Motzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT01491672
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 611)
DOI
10.1200/jco.2016.34.2_suppl.611
Abstract #
611
Poster Bd #
J8
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.
First Author: Thomas Cosgriff
Poster
2015 ASCO Annual Meeting
RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Robert Motzer
Poster
2018 Genitourinary Cancers Symposium
Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
First Author: Paul L. de Souza
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu